Non-interventional Study (NIS) in Patients With Restless Legs Syndrome in Daily Practise
Non-interventional Study (NIS) in Patients With Restless Legs Syndrome in Daily Practise
This non-interventional observational study is designed to gain data for Neupro® in restless
 legs syndrome (RLS) under real life conditions in line with the summary of product
 characteristics (SmPC) related to effectiveness, tolerability and switching practice from
 other dopaminergic drugs as well as titration schemes.
There is a total of 64 subjects recorded as having discontinued due to Adverse Events.
 Documentation of Visit 2 and Visit 3, where the reason for discontinuation was documented,
 was not available for all subjects. From the documentation on the Adverse Events page in the
 Case Report Form, it is known that 100 subjects discontinued due to Adverse Events.

 The Last Observation Carried Forward (LOCF) method was utilized for all outcomes.
Inclusion Criteria:

 -  It was recommended that the patient's treatment was in accordance with the local
 marketing authorization (MA) for Neupro®

 -  The patient must have a diagnosis of moderate to severe idiopathic RLS

 -  The patient is considered reliable and capable of adhering to the visit schedule or
 medication administration according to the judgment of the investigator

 -  The decision to prescribe the drug has been made by the physician independently of
 his/her decision to include the patient in the study

 -  Subject is informed and given ample time and opportunity to think about his/her
 participation in the study and has given written informed data consent

 Exclusion Criteria:

 -  Hypersensitivity to the active substance or to any of the excipients

 -  Magnetic resonance imaging or cardioversion (see SmPC)